Agonist– tag –
-
The Rise of Oral GLP-1 Receptor Agonists: Transforming Diabetes and Obesity Treatment Convenience from Injections to Pills
Pharmacy Times USA Overview The advent of oral GLP-1 receptor agonists (GLP-1RAs) is fundamentally transforming drug administration in diabetes and obesity treatment. Oral formulations are rapidly gaining traction in the previously injec... -
GLP-1 Receptor Agonists Expand Therapeutic Scope to MASH: Novo Nordisk’s Wegovy First FDA-Approved for MASH, Eli Lilly’s Oral Foundayo Launched
Drug Discovery Trends USA Overview The therapeutic scope of GLP-1 receptor agonists has expanded beyond diabetes and obesity to include cardiovascular risk, obstructive sleep apnea, chronic kidney disease, and by 2025, MASH (Metabolic Dy... -
Oral GLP-1 Agonist Semaglutide Success Drives Peptide Drug Discovery Transformation: AI Design, Unnatural Amino Acids, and Nanocarriers Enhance Oral Bioavailability
Bhunia Lab Unknown Overview While peptide therapeutics have advanced significantly, oral delivery remains a challenge. The success of oral semaglutide demonstrates how chemical modifications like amino acid substitutions and fatty acid a... -
Oral GLP-1 Aleniglipron Achieves 12% Weight Loss in Phase II, Poised to Transform Obesity Treatment
Health and Me / Northwestern University USA Overview The novel oral GLP-1 receptor agonist, aleniglipron, demonstrated an impressive average 12% body weight reduction over 36 weeks in obese or overweight patients during a Phase II clinic... -
Novo Nordisk’s Zenagamutide: Dual GLP-1/Amylin Agonist Delivers Significant Metabolic Gains in Type 2 Diabetes
Healio デンマーク Overview Novo Nordisk's novel unimolecular GLP-1/amylin receptor agonist, zenagamutide, has demonstrated significant reductions in HbA1c and body weight in adults with type 2 diabetes during its Phase 2 clinical trial. ... -
Precision Science Fuels Biopharma M&A Surge: Q1 2026 Hits $65B+, Marking Industry’s ‘Full Recovery’
BioSpace / PwC, Pharmaceutical Technology / PwC USA Overview PwC's latest report declares the biopharma ecosystem 'fully recovered,' with Q1 2026 M&A deal values exceeding $65 billion, marking the largest quarter since 2020. This rob... -
Oral GLP-1 Agonist Elecoglipron Achieves Landmark 11.8% Weight Loss and Superior Glycemic Control in Phase 2 Trial
News-Medical.Net 他 USA Overview The oral GLP-1 receptor agonist elecoglipron delivered compelling results in its Phase 2b SOLSTICE clinical trial, achieving up to 11.8% dose-dependent body weight reduction and significantly improving gl... -
Novo Nordisk’s Oral Wegovy Approved in UK, Becoming Europe’s First Oral GLP-1 Obesity Treatment
Clinical Research News UK Overview Novo Nordisk's oral GLP-1 receptor agonist, Wegovy (semaglutide tablet), has received approval in the UK, marking its entry as the first oral obesity medication in Europe. This approval is expected to s... -
Oral GLP-1 Receptor Agonist Elecoglipron Achieves Up to 11.8% Weight Loss and 7% Blood Sugar Reduction in Phase 2b Trials
Medical News Today (citing The Lancet) International Overview Once-daily oral GLP-1 receptor agonist elecoglipron demonstrated significant efficacy in its Phase 2b SOLSTICE clinical trial. Obese and overweight adults achieved up to an 11... -
GLP-1 Market Heats Up with Oral Therapies and Triple Agonists for Obesity, Metabolic Health Opportunity Nears $150 Billion
DataM Intelligence USA Overview The GLP-1 market is experiencing intense competition, driven by the development of oral therapies and triple agonists for obesity and metabolic health, with the market opportunity projected to reach $150 b...
